Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL ALLERGY AND CONGESTION RELIEF vs ACTIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Temporary relief of symptoms due to hay fever or other upper respiratory allergies: nasal congestion, sinus pressure, sneezing, runny nose, itching of nose or throat, and itchy, watery eyes due to allergies.,Temporary reduction of fever.,Relief of minor aches and pains associated with the common cold, headache, toothache, muscular aches, backache, menstrual cramps, and arthritis pain.
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
Ibuprofen: 2-4 hours; pseudoephedrine: 5-8 hours. Shorter half-life requires frequent dosing for sustained relief.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Ibuprofen is primarily metabolized by cytochrome P450 (CYP) enzymes, mainly CYP2C9, to inactive metabolites (hydroxyibuprofen and carboxyibuprofen). Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Renal excretion of unchanged drug and metabolites; approximately 1% excreted unchanged (pseudoephedrine) and 15% (ibuprofen). Biliary/fecal elimination accounts for <5%.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Ibuprofen: 99% bound to albumin; pseudoephedrine: negligible protein binding.
Approximately 90% bound to plasma proteins, primarily albumin.
Ibuprofen: 0.1-0.2 L/kg; pseudoephedrine: 2.5-3 L/kg.
2.5-4.0 L/kg, indicating extensive tissue distribution.
Oral: ibuprofen 80-100%; pseudoephedrine 100%.
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
For pseudoephedrine: Cr Cl <30 m L/min, reduce dose by 50% or administer every 12 hours. For ibuprofen: avoid use if Cr Cl <30 m L/min; if Cr Cl 30-59 m L/min, use lowest effective dose and monitor renal function.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
For ibuprofen: Child-Pugh class A and B: no adjustment necessary; Child-Pugh class C: avoid use. For pseudoephedrine: use with caution in severe hepatic impairment; no specific dose adjustment recommended, but monitor for adverse effects.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Not indicated for children under 12 years of age. For children 12 years and older: same as adult dose (1-2 tablets every 4-6 hours, max 6 tablets per day). Weight-based: not routinely used; safety and efficacy not established for <25 kg.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
For ibuprofen: use lowest effective dose for shortest duration; monitor renal function and GI bleeding risk. For pseudoephedrine: initiate at lower doses (e.g., one tablet every 6 hours) due to increased sensitivity and risk of hypertension, urinary retention, and CNS effects.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
Cardiovascular risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for perioperative pain in coronary artery bypass graft (CABG) surgery. Gastrointestinal risk: NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and those with prior peptic ulcer disease and/or GI bleeding are at greater risk.
None
Cardiovascular effects: may increase risk of heart attack or stroke; use lowest effective dose for shortest duration. Gastrointestinal effects: may cause GI ulceration, bleeding, perforation. Renal effects: avoid in advanced renal disease; monitor renal function. Hepatic effects: may cause liver enzyme elevation; discontinue if liver disease develops. Anaphylactic reactions: may occur in patients with or without prior NSAID sensitivity. Asthma: may cause bronchospasm. Hypertension: may worsen hypertension. Avoid in late pregnancy due to risk of premature closure of ductus arteriosus. Pseudoephedrine: may cause nervousness, dizziness, insomnia, hypertension, arrhythmias; use with caution in patients with cardiovascular disease, diabetes, glaucoma, prostatic hypertrophy, hyperthyroidism. Avoid in severe hypertension or coronary artery disease.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Hypersensitivity to ibuprofen, pseudoephedrine, or any component of the formulation. History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs. In the setting of coronary artery bypass graft (CABG) surgery. Severe hypertension. Coronary artery disease. Concurrent use with or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis. Pregnancy (third trimester).
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Take with food or milk to minimize GI upset. Avoid alcohol as it may increase risk of GI bleeding. No specific food-drug interactions.
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolonged use due to potential oligohydramnios. Third trimester: NSAIDs (including ibuprofen) are contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios. Pseudoephedrine: Limited data; possible association with gastroschisis if used in first trimester; avoid due to vasoconstrictive effects.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
Ibuprofen: Excreted in low levels (M/P ratio ~0.006); considered compatible with breastfeeding. Pseudoephedrine: Excreted in breast milk (M/P ratio ~2.5-3.5); may reduce milk production and cause irritability in infants; use with caution.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
Ibuprofen: No specific dose adjustment recommended for pregnancy; however, avoid use in third trimester. Pseudoephedrine: No dose adjustment studied; use lowest effective dose for shortest duration. Neither drug is recommended for regular use during pregnancy.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
Combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen may increase blood pressure, counteracting pseudoephedrine's vasoconstriction; monitor in hypertensive patients. Avoid in patients with severe CAD, uncontrolled HTN, or within 2 weeks of MAOI use.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
Do not take with other NSAIDs or cold/flu products to avoid overdose.,Pseudoephedrine may cause insomnia; take last dose at least 4-6 hours before bedtime.,Ibuprofen can cause GI bleeding; take with food or milk to reduce risk.,Stop use and consult doctor if symptoms persist >7 days or if fever lasts >3 days.,Avoid alcohol while taking this medication.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL ALLERGY AND CONGESTION RELIEF vs ACTIDIL, answered by our medical review team.
ADVIL ALLERGY AND CONGESTION RELIEF is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.. ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL ALLERGY AND CONGESTION RELIEF and ACTIDIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL ALLERGY AND CONGESTION RELIEF is: Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.. The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL ALLERGY AND CONGESTION RELIEF and ACTIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL ALLERGY AND CONGESTION RELIEF is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolo. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.